Safeguarding Patients in Clinical Trials with High Mortality Rates

*Blog post
2015
Blinding in research
Early stopping
Ethics in research
Author

Steve Simon

Published

December 2, 2015

Figure 1. First page of research article

This is an article the I would trot out if anyone tried to argue that a Data Safety and Monitoring Board should, like the investigators, be blinded as to treatment status during their deliberations.

Bradley D. Freeman, Robert L. Danner, Steven M. Banks, and Charles Natanson “Safeguarding Patients in Clinical Trials with High Mortality Rates” American Journal of Respiratory and Critical Care Medicine, Vol. 164, No. 2 (2001), pp. 190-192. doi: 10.1164/ajrccm.164.2.2011028. Available in html format.

Earlier versions are here and here.